Blog
    Regulatory UpdateFor PhysiciansApril 8, 2026

    FDA peptide compounding status and GLP-1 safety data

    Review FDA Category 2 classifications for BPC-157 and TB-500 alongside FAERS safety signals for Semaglutide, including NAION and pulmonary aspiration risks.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    1. Clinical Question

    What is the current regulatory landscape and safety profile for commonly utilized peptides, and how do FDA compounding classifications impact their clinical availability as of March 2026?

    2. Evidence Snapshot

    • Study Types: Phase II/III clinical trials, FDA Adverse Event Reporting System (FAERS) data, and FDA regulatory records.
    • Total Adverse Event Reports (GLP-1 RA): 187,757 through 2023.
    • Regulatory Classifications: FDA Category 2 listing for multiple peptides (ineligible for routine compounding).
    • Key Outcomes: Clinical efficacy ranges from 14.9% to 24.2% weight loss in Phase II/III trials for obesity-focused peptides; negative mortality outcomes for others.

    3. What the Research Shows

    Regulatory and Compounding Status As of March 2026, the FDA has classified several peptides under Category 2 (Sept 2023), designating them as substances with significant safety risks that are ineligible for routine compounding under Section 503A or 503B.

    BPC-157 is currently listed as a Category 2 bulk substance due to immunogenicity concerns and a lack of safety data. It has also been the subject of multiple warning letters, including a 2020 letter to Tailor Made Compounding and Predator Nutrition in October 2020. Similarly, TB-500 holds Category 2 status with the FDA citing immunogenicity risks and an absence of human exposure data.

    Several peptides previously nominated for compounding have seen their nominations withdrawn or their status changed. Thymosin Alpha-1 was moved to Category 2 in September 2023 and subsequently removed pending advisory review in September 2024, though it remains a substance of concern under interim policy. AOD-9604, CJC-1295, Ipamorelin, and Selank all had their nominations withdrawn or were removed in September 2024. Ipamorelin and GHK-Cu maintain Category 2 status for 503B facilities.

    Safety Signal Analysis Evaluation of the FAERS database reveals significant signals for Semaglutide, particularly concerning gastrointestinal effects. Strong signals (elevated ROR) are recorded for nausea, vomiting, and delayed gastric emptying. Pancreatitis shows a moderate signal (elevated PRR), while intestinal obstruction (ileus) is noted as an emerging signal added to postmarketing labels.

    Non-gastrointestinal signals have also emerged. For Semaglutide, nonarteritic anterior ischemic optic neuropathy (NAION) is an emerging signal under EMA review as of January 2025 (96 cases through December 2024). Pulmonary aspiration was added to the Ozempic label in 2025 due to risks during general anesthesia associated with delayed gastric emptying.

    Clinical Trial Results In Phase III obesity trials, Semaglutide (STEP 1) demonstrated 14.9% weight loss, and Tirzepatide (SURMOUNT-1) showed 22.5% weight loss. Retatrutide, currently in Phase III (TRIUMPH-3), showed 24.2% weight loss at 12mg in Phase II trials. In contrast, Thymosin Alpha-1 failed to demonstrate a reduction in mortality in Phase III sepsis trials (NCT02867267).

    4. Mechanism

    Mechanistic data provided focuses on the physiological impacts and risks of specific peptides. Semaglutide and related GLP-1 RAs contribute to delayed gastric emptying, which may impact the absorption of oral medications and increase the risk of pulmonary aspiration during anesthesia.

    Safety concerns for BPC-157, TB-500, GHK-Cu, and GHRP-2 are characterized primarily by immunogenicity risks. For CJC-1295, the FDA cited safety issues including increased heart rate. Tesamorelin has demonstrated a 18% reduction in visceral adipose tissue (VAT) in pivotal Phase III trials for HIV lipodystrophy.

    5. Limitations of the Evidence

    There is a notable lack of human exposure data for several peptides including TB-500. While some peptides like Selank and Semax are approved in Russia for indications such as stroke, they are not FDA-approved. For Semaglutide, current data on suicidal ideation do not support a higher risk compared to background rates, although the FDA requires ongoing monitoring. Many newer peptides, such as Retatrutide, are still in active Phase III recruitment (TRIUMPH-3), meaning long-term safety and efficacy data remain incomplete.

    6. Clinical Takeaway

    The regulatory environment for compounded peptides is restrictive, with many substances categorized under FDA Category 2 due to safety or immunogenicity concerns. For approved GLP-1 RAs, gastrointestinal signals are strong and dose-dependent, with emerging signals like NAION and pulmonary aspiration requiring clinical vigilance. Clinicians should monitor for obstruction symptoms and consider the implications of delayed gastric emptying for surgical patients.

    7. Sources

    • REGULATORY STATUS RECORDS (ID: 0abdad3c, 68b0b103, c8181049, 96fb1240, 1a160b34, 116a4f32, 856316f2, fe228995, a11f0210, a6e75c1b)
    • FAERS SAFETY SIGNALS (ID: 502f8ab5, 0296a263, d2135902, 4f021484, 3c2b6572, bcece5fd, afc343ed, be753983, 99f7d6d6, 60c7beaa)
    • CLINICAL TRIAL RECORDS (NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT059290, NCT00451282, NCT02867267)

    Referenced Peptides

    bpc 157semaglutidetirzepatideretatrutidethymosin alpha 1tb 500

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.